TY - JOUR
TI - Bortezomib Plus Melphalan--Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan--Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.
AU - Mateos, Maria-Victoria
AU - Richardson, Paul G
AU - Schlag, Rudolf
AU - Khuageva, Nuriet K
AU - Dimopoulos, Meletios A
AU - Shpilberg, Ofer
AU - Kropff, Martin
AU - Spicka, Ivan
AU - Petrucci, Maria Teresa
AU - Palumbo, Antonio
AU - others
JO - Blood cancer journal
PY - 2009
VL - 114
TODO - 22
SP - 3859
PB - Content Repository Only!
SN - null
TODO - null
TODO - null
TODO - null
ER -